APTI

Advanced Proteome Therapeutics Announces Appointment of Dr. Benjamin Krantz to CEO

Wednesday, July 21, 2021 - 1:30pm

Burnaby, British Columbia--(Newsfile Corp. - July 21, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that as previously planned, Dr. Benjamin Krantz has taken over the role of CEO at its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").

Key Points: 
  • Burnaby, British Columbia--(Newsfile Corp. - July 21, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that as previously planned, Dr. Benjamin Krantz has taken over the role of CEO at its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").
  • Since the initial announcement of Dr. Krantz' planned appointment on December 17, 2020, he has been working diligently in preparation for this transition.
  • Dr. Benjamin Krantz, Director and CEO stated, "I am extremely excited to be taking on the role of CEO at APTI.
  • Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads.

Advanced Proteome Therapeutics Announces Renowned Scientist to Join Scientific Advisory Board and New Chemistry Hire

Wednesday, June 9, 2021 - 6:40pm

Vancouver, British Columbia--(Newsfile Corp. - June 9, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has a appointed a new Scientific Advisory Board Member and hired a new lead chemist.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - June 9, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has a appointed a new Scientific Advisory Board Member and hired a new lead chemist.
  • APTI is pleased to report that Dr. Ravi Chari is joining the Company's Scientific Advisory Board and Dr. Rajeshkumar Manian is joining as the lead organic chemist.
  • Dr. Chari is a giant in the ADC space and brings a wealth of experience to his role on the Scientific Advisory Board.
  • Dr. Ravi Chari, "I am delighted to be joining the Advanced Proteome Therapeutics Scientific Advisory Board.

Advanced Proteome Therapeutics Announces Dr. Benjamin Krantz to Join Company as CEO

Thursday, December 17, 2020 - 6:02pm

Burnaby, British Columbia--(Newsfile Corp. - December 17, 2020) - Advanced Proteome Therapeutics Corporation(TSXV: APC) (FSE: 0E8)("APC" or the "Company'), is pleased to announce that Dr. Benjamin Krantz will be joining the Company's US subsidiary Advanced Proteome Therapeutics Inc. ("APTI") as CEO following the completion of his oncology fellowship at NYU Langone Health on July 1st, 2021.

Key Points: 
  • Burnaby, British Columbia--(Newsfile Corp. - December 17, 2020) - Advanced Proteome Therapeutics Corporation(TSXV: APC) (FSE: 0E8)("APC" or the "Company'), is pleased to announce that Dr. Benjamin Krantz will be joining the Company's US subsidiary Advanced Proteome Therapeutics Inc. ("APTI") as CEO following the completion of his oncology fellowship at NYU Langone Health on July 1st, 2021.
  • Benjamin Krantz MD, MBA is the Chief Fellow in hematology/oncology at New York University Langone Medical Center and is currently on the Board of Directors at APTI.
  • Dr. Krantz states, "I am thrilled to be taking on the role of CEO at APTI on completion of my oncology fellowship.
  • Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates improved site-selective labeling, drug-antibody ratio control and enabling of combination payloads.